Asia Hepatitis Drugs Market Expected to Witness the Fastest Growth (32.4% CAGR) Globally During 2015 – 2020

The global hepatitis drugs market was valued at $23,222.1 million in 2014, and it is expected to grow with a CAGR of 29.7% during 2015 - 2020. The global hepatitis drugs market is growing due to increasing incidences of hepatitis and increasing support from government organizations. In addition, the growing geriatric population, and increasing R&D investments on hepatitis research and drug discovery are also driving the growth of the global hepatitis drugs market.

Among the various types, the hepatitis C segment is expected to be the largest segment, and expected to witness the fastest growth during the forecast period, with a CAGR of 30.7%.

Explore Report with Detailed TOC on “Global Hepatitis Drugs Market” at: www.psmarketresearch.com/market-analysis/-hepatitis-drugs-market

The increasing incidences of various types of hepatitis, such as hepatitis B, and hepatitis C are playing a pivotal role in the growth of the global hepatitis drugs market. According to the Hepatitis B Foundation, a non-profit organization solely dedicated to the global problem of hepatitis B, approximately 400 million people globally were chronically infected with hepatitis B, as reported at the end of September 2015. According to the World Health Organization (WHO), an estimated 130 - 150 million people globally were reported to suffer from hepatitis C, as of July 2015. The increasing incidences of hepatitis have increased the demand of therapeutic drugs for the management of diseases.
However, the high capital expenditure and stringent regulatory requirements are inhibiting the growth of the market. The growing number of collaboration and partnerships is one of the latest trends observed in the market.

Ask for Sample Pages: www.psmarketresearch.com/market-analysis/-hepatitis-drugs-market/report-sample

Geographically, North America dominated the global market of hepatitis drugs in 2014; whereas the Asian market is expected to witness the fastest growth, with a CAGR of 32.4% during the forecast period.

The key companies operating in the global hepatitis drugs market include Gilead Sciences Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co. Inc., GlaxoSmithKline PLC, AbbVie Inc., Novartis AG, Bristol-Myers Squibb Company, Dynavax Technologies Corporation, and Mitsubishi Tanabe Pharma Corporation.

Browse More Report on Healthcare at: www.psmarketresearch.com/industry-report/healthcare

GLOBAL HEPATITIS DRUGS MARKET SEGMENTATION
By Type

 Hepatitis A
 Hepatitis B
 Hepatitis C
 Others

By Drug
 Hepatitis B Drugs
o Baraclude
o Viread
o Pegasys
o Tyzeka
o Hepsera
o Others

 Hepatitis C Drugs
o Sovaldi
o OLYSIO
o Harvoni
o Pegasys
o PegIntron
o Victrelis
o Others

Breakdown by Geography
 North America
o The U.S.
o Canada
o Rest of North America

 Europe
o Germany
o France
o The U.K.
o Rest of Europe

 Asia
o Japan
o China
o India
o Rest of Asia
 Rest of the World (RoW)

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
Deep
Assistant – Client Partner
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Web: www.psmarketresearch.com

347 5th Ave. #1402- 210
New York City
United States

This release was published on openPR.